MILESTONE PHARMACEUTICALS IN's ticker is MIST and the CUSIP is 59935V107. A total of 30 filers reported holding MILESTONE PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $18,380,000 | +18.1% | 2,000,000 | -20.9% | 0.88% | +14.4% |
| Q2 2022 | $15,560,000 | -4.2% | 2,530,003 | 0.0% | 0.77% | -10.6% |
| Q1 2022 | $16,243,000 | -2.0% | 2,530,003 | -0.0% | 0.86% | +9.2% |
| Q4 2021 | $16,575,000 | +14.7% | 2,530,585 | 0.0% | 0.78% | +5.1% |
| Q3 2021 | $14,450,000 | +3.8% | 2,530,585 | 0.0% | 0.75% | +21.1% |
| Q2 2021 | $13,918,000 | -5.0% | 2,530,585 | 0.0% | 0.62% | +2.0% |
| Q1 2021 | $14,652,000 | -13.6% | 2,530,585 | 0.0% | 0.60% | -16.8% |
| Q4 2020 | $16,955,000 | +11.3% | 2,530,585 | +21.6% | 0.73% | -3.8% |
| Q3 2020 | $15,230,000 | +93.6% | 2,080,585 | 0.0% | 0.76% | +48.8% |
| Q2 2020 | $7,865,000 | +105.5% | 2,080,585 | 0.0% | 0.51% | +99.2% |
| Q1 2020 | $3,828,000 | -90.2% | 2,080,585 | -14.5% | 0.26% | -89.8% |
| Q4 2019 | $38,976,000 | -21.9% | 2,434,470 | -9.0% | 2.51% | -70.6% |
| Q3 2019 | $49,879,000 | -31.3% | 2,674,470 | 0.0% | 8.54% | -16.0% |
| Q2 2019 | $72,612,000 | – | 2,674,470 | – | 10.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ikarian Capital, LLC | 1,750,043 | $11,464,000 | 1.71% |
| Novo Holdings A/S | 2,530,585 | $16,575,000 | 0.78% |
| Boxer Capital, LLC | 2,238,861 | $14,665,000 | 0.57% |
| RTW INVESTMENTS, LP | 4,315,102 | $28,264,000 | 0.41% |
| RA Capital Management | 2,246,503 | $14,715,000 | 0.26% |
| Bleichroeder LP | 250,000 | $1,638,000 | 0.26% |
| PURA VIDA INVESTMENTS, LLC | 931,511 | $6,101,000 | 0.22% |
| Orbimed Advisors | 2,583,821 | $16,924,000 | 0.22% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 851,291 | $5,576,000 | 0.11% |
| Eversept Partners, LP | 147,165 | $963,931 | 0.06% |